SCHEMBL143999

SCHEMBL143999

O=C(O)c1cccc2c1[nH]c1ccccc12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 2/20 0.78
MPL P40238 1/20 0.57
GFER P55789 2/20 0.57
MAPT P10636 2/20 0.57
PIM1 P11309 2/20 0.57
KDM4E B2RXH2 2/20 0.57
TDP1 Q9NUW8 2/20 0.57
PARP1 P09874 1/20 0.54
KIF11 P52732 4/20 0.52
APP P05067 1/20 0.51
NR4A1 P22736 1/20 0.50
NR4A2 P43354 1/20 0.50
NR4A3 Q92570 1/20 0.50
PIM3 Q86V86 1/20 0.50
JAK2 O60674 1/20 0.50
TP53 P04637 1/20 0.50
HTT P42858 1/20 0.50
KLK7 P49862 1/20 0.50
PARP14 Q460N5 2/20 0.49
FGFR1 P11362 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30455267 1.00 PBRM1 (0.78) PBRM1MPLGFERMAPTPIM1
SCHEMBL29844370 1.00 PBRM1 (0.78) PBRM1MPLGFERMAPTPIM1
SCHEMBL11801609 0.90 PBRM1 (0.65) PBRM1MPLGFERMAPTPIM1
SCHEMBL4943278 0.88 PBRM1 (1.00) PBRM1MPLGFERMAPTPIM1
SCHEMBL29801740 0.88 PBRM1 (1.00) PBRM1MPLGFERMAPTPIM1
SCHEMBL29043472 0.88 PBRM1 (0.62) PBRM1MPLGFERMAPTPIM1
SCHEMBL4654498 0.87 PBRM1 (0.60) PBRM1MPLMAPTPIM1KIF11
SCHEMBL21749209 0.86 PBRM1 (0.60) PBRM1MPLPARP1PARP14
SCHEMBL6887279 0.85 PBRM1 (0.58) PBRM1MPLMAPTPIM1KIF11
SCHEMBL31485136 0.84 PBRM1 (0.58) PBRM1MPLMAPTPIM1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105646330-A Heteroaromatic ring derivative and application thereof in drug 贵州医科大学 2016-06-08 CN claimed
CN-105439938-A Novel carbazole carboxylate compounds and synthetic method therefor UNIV BEIJING TECHNOLOGY 2016-03-30 CN claimed
EP-1599202-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-11-30 EP claimed
WO-2004071507-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2004-08-26 WO claimed
EP-0725651-B1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORP (US) 1999-08-11 EP claimed
US-5830867-A Hemoregulatory peptides for stimulating the myelopoietic system SMITHKLINE BEECHAM CORPORATION (US) 1998-11-03 US claimed
US-5652219-A Hemoregulatory peptides SMITHKLINE BEECHAM CORPORATION (US) 1997-07-29 US claimed
EP-0701446-A4 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORP (US) 1997-04-23 EP claimed
EP-0725651-A4 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORP (US) 1997-03-05 EP claimed
EP-0621788-A4 HEMOREGULATORY PEPTIDES. SMITHKLINE BEECHAM CORP (US) 1997-03-05 EP claimed
EP-0725651-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1996-08-14 EP claimed
EP-0701446-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1996-03-20 EP claimed
WO-1995011693-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1995-05-04 WO claimed
WO-1994027627-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1994-12-08 WO claimed
EP-0621788-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1994-11-02 EP claimed
CN-1077960-A HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORP (US) 1993-11-03 CN claimed
WO-1993013789-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1993-07-22 WO claimed
US-12319661-B2 Polycyclic compound EUTEC NEW MATERIALS TECHNOLOGY (SUZHOU) CO., LTD. (CN) 2025-06-03 US disclosed
US-4057640-A ANTIINFLAMMATORY SCHERING AKTIENGESELLSCHAFT (DT) 1977-11-08 US disclosed
US-3956295-A ANTIINFLAMMATORY SCHERING AKTIENGESELLSCHAFT (DT) 1976-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12319661-B2 Polycyclic compound CUTA, CDH1, DSG1 PBRM1 42/4885MPL 4714/4885GFER 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.